Squamoid Eccrine Ductal Carcinoma: Treatment and Outcomes.
Am J Dermatopathol
; 44(4): 249-253, 2022 Apr 01.
Article
in En
| MEDLINE
| ID: mdl-35287138
BACKGROUND: Squamoid eccrine ductal carcinoma (SEDC) represents a subtype of eccrine carcinomas that are diagnostically challenging for both clinicians and dermatopathologists. OBJECTIVE: To provide an updated review of SEDC and examine patient outcomes with different treatment modalities. METHODS: A review of Ovid MEDLINE was performed to review the English language medical literature of SEDC. RESULTS: A comprehensive review of clinical presentation, histologic findings, rates of lymphovascular and metastatic disease, treatment modalities and recurrence rates are reviewed. LIMITATIONS: There is a limitation on available data because of the rare incidence. CONCLUSIONS: SEDC is a rare adnexal neoplasm with a relatively high rate of local recurrence, lymphovascular invasion, perineural invasion, and metastases. Clinicians should be aware of this entity as close follow-up is essential to detect recurrence and metastatic disease. Mohs micrographic surgery seems to result in superior patient outcomes.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sweat Gland Neoplasms
/
Carcinoma, Squamous Cell
/
Carcinoma, Ductal
/
Eccrine Glands
Type of study:
Diagnostic_studies
Limits:
Aged
/
Humans
/
Male
Language:
En
Journal:
Am J Dermatopathol
Year:
2022
Type:
Article
Affiliation country:
Canada